Vigil Neuro Overview
- Year Founded
-
2020
- Status
-
Acquired/Merged
- Employees
-
67
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$443M
Vigil Neuro General Information
Description
Operator of a clinical-stage biotechnology company focused on developing treatments intended for both rare and common neurodegenerative diseases.
Contact Information
Website
www.vigilneuro.comCorporate Office
- 100 Forge Road
- Suite 700
- Watertown, MA 02472
- United States
Corporate Office
- 100 Forge Road
- Suite 700
- Watertown, MA 02472
- United States
Vigil Neuro Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 05-Aug-2025 | $443M | Completed | Generating Revenue | ||
| 5. PIPE | 09-Jul-2024 | Completed | Generating Revenue | |||
| 4. PIPE | 16-Aug-2022 | Completed | Generating Revenue | |||
| 3. IPO | 07-Jan-2022 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series B) | 13-Aug-2021 | $90M | $140M | Completed | Clinical Trials - Phase 1 | |
| 1. Early Stage VC (Series A) | 08-Dec-2020 | $50M | $50M | Completed | Clinical Trials - Phase 1 |
Vigil Neuro Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
Vigil Neuro Comparisons
Industry
Financing
Details
Vigil Neuro Competitors (11)
One of Vigil Neuro’s 11 competitors is Muna Therapeutics, a Venture Capital-Backed company based in Frederiksberg, Denmark.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Muna Therapeutics | Venture Capital-Backed | Frederiksberg, Denmark | ||||
| CAMP4 | Formerly VC-backed | Cambridge, MA | ||||
| Alector | Formerly VC-backed | South San Francisco, CA | ||||
| Prevail Therapeutics | Formerly VC-backed | New York, NY | ||||
| Johnson&Johnson Innovative Medicine | Venture Capital-Backed | Raritan, NJ |
Vigil Neuro Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Vigil Neuro Patents
Vigil Neuro Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026198852-A1 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | Pending | 21-Mar-2025 | ||
| WO-2026198853-A2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | Pending | 21-Mar-2025 | ||
| WO-2026198853-A3 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | Pending | 21-Mar-2025 | ||
| WO-2026024901-A1 | Methods of using bicyclic compounds as triggering receptor expressed on myeloid cells (trem2) agonists | Pending | 23-Jul-2024 | ||
| AU-2024399431-A1 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | Pending | 12-Dec-2023 | C07D471/04 |
Vigil Neuro Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Vigil Neuro Former Investors (18)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Atlas Venture | Venture Capital | Minority | ||
| BVF Partners | Hedge Fund | Minority | ||
| Cormorant Asset Management | PE/Buyout | Minority | ||
| DAFNA Capital Management | Hedge Fund | Minority |
Vigil Neuro ESG
Risk Overview
Risk Rating
Updated November, 08, 2026
13.5 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Vigil Neuro FAQs
-
When was Vigil Neuro founded?
Vigil Neuro was founded in 2020.
-
Where is Vigil Neuro headquartered?
Vigil Neuro is headquartered in Watertown, MA.
-
What is the size of Vigil Neuro?
Vigil Neuro has 67 total employees.
-
What industry is Vigil Neuro in?
Vigil Neuro’s primary industry is Drug Discovery.
-
Is Vigil Neuro a private or public company?
Vigil Neuro is a Private company.
-
What is the current valuation of Vigil Neuro?
The current valuation of Vigil Neuro is .
-
What is Vigil Neuro’s current revenue?
The current revenue for Vigil Neuro is .
-
How much funding has Vigil Neuro raised over time?
Vigil Neuro has raised $353M.
-
Who are Vigil Neuro’s investors?
Alexandria Venture Investments, Atlas Venture, BVF Partners, Cormorant Asset Management, and DAFNA Capital Management are 5 of 18 investors who have invested in Vigil Neuro.
-
Who are Vigil Neuro’s competitors?
Muna Therapeutics, CAMP4, Alector, Prevail Therapeutics, and Johnson&Johnson Innovative Medicine are some of the 11 competitors of Vigil Neuro.
-
When was Vigil Neuro acquired?
Vigil Neuro was acquired on 05-Aug-2025.
-
Who acquired Vigil Neuro?
Vigil Neuro was acquired by Sanofi.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
